Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sight Sciences ( (SGHT) ) has issued an update.
On October 17, 2025, Sight Sciences announced that Novitas Solutions and First Coast Service Options established jurisdiction-wide pricing for the TearCare System procedure under CPT code 0563T, effective January 1, 2025. This development, covering 10.4 million Medicare beneficiaries, is expected to enhance patient access to the TearCare procedure, supporting the company’s engagement with third-party payors and clinical societies.
The most recent analyst rating on (SGHT) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
Sight Sciences’ overall stock score reflects a stable financial position with strong gross margins and liquidity, but is weighed down by declining revenues, persistent losses, and negative cash flows. The technical analysis suggests a neutral trend, while the valuation is challenged by a negative P/E ratio. The earnings call provided some optimism with raised revenue guidance and strategic initiatives, but challenges in certain segments remain.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative, interventional solutions to transform care and improve patients’ lives. The company offers products like the OMNI Surgical System for glaucoma treatment and the TearCare System for evaporative dry eye disease, aiming to create more effective treatment paradigms.
Average Trading Volume: 110,418
Technical Sentiment Signal: Sell
Current Market Cap: $180.7M
For detailed information about SGHT stock, go to TipRanks’ Stock Analysis page.